文献速递慢阻肺

髓过氧化物酶抑制剂米替哌司特治疗慢阻肺的2a期随机对照试验

A phase 2a, double-blind, randomised, placebo-controlled trial of the myeloperoxidase inhibitor, mitiperstat, in participants with chronic obstructive pulmonary disease.
PubMed 文献 · Eur Respir J · 2026-08-06

这项2a期随机双盲安慰剂对照试验纳入381例中重度慢阻肺急性加重高风险成人,评估米替哌司特5mg每日一次最长24周的疗效与安全性。结果显示米替哌司特未改善首次COPD综合终点事件时间(HR 1.07,90%CI 0.87-1.32;p=0.599),也未改善肺功能、症状或疾病影响。结论认为该药治疗慢阻肺风险大于获益。

要点

  • 米替哌司特未延长首次COPD综合终点事件时间,HR 1.07(90%CI 0.87-1.32;p=0.599)。
  • 米替哌司特组肺炎7例,安慰剂组2例,安全性需关注。
  • 该药未改善支气管舒张后FEV1、呼吸道症状或疾病影响。

核心结论

  • 米替哌司特治疗慢阻肺的风险大于获益。

研究设计与样本

  • 2a期随机、安慰剂对照、双盲、平行组、事件驱动试验(NCT05492877)。
  • 纳入381例40-80岁中重度慢阻肺、急性加重高风险且接受双联或三联吸入治疗的成人。
  • 米替哌司特5mg每日一次最长24周(n=189)对比安慰剂(n=192)。

主要发现

  • 24周内米替哌司特组125例(66.1%)、安慰剂组125例(65.1%)发生COPD综合终点事件。
  • 首次COPD综合终点事件时间无改善:HR 1.07(90%CI 0.87,1.32;p=0.599)。
  • 首次中重度慢阻肺急性加重时间无改善:HR 1.23(90%CI 0.88,1.73)。
  • 未观察到支气管舒张后FEV1、呼吸道症状或疾病影响的改善。
  • 两组不良事件比例相似;米替哌司特组7例、安慰剂组2例发生肺炎。

临床怎么用

  • 不推荐米替哌司特用于中重度慢阻肺急性加重高风险患者的治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neutrophilic inflammation is a common feature of chronic obstructive pulmonary disease (COPD). Mitiperstat, an inhibitor of myeloperoxidase expressed in neutrophils, may have potential as a COPD treatment. METHODS: This phase 2a, randomised, placebo-controlled, double-blind, parallel-arm, event-driven trial evaluated the efficacy and safety of mitiperstat 5 mg daily up to 24 weeks (NCT05492877). Adults (40-80 years) with moderate-to-severe COPD, at high risk of exacerbation, and receiving dual or triple inhaled therapy were included. The primary endpoint was time to first composite endpoint for exacerbations in COPD (COPDCompEx) event. Secondary endpoints included time to first moderate-to-severe COPD exacerbation, post-bronchodilator forced expiratory volume in 1 s (post-BD FEV1) change at Week 12, respiratory symptoms, disease impact and safety. RESULTS: Overall, 381 participants (mean age, 66.0 years; 39.6% female) were randomised to mitiperstat (n=189) or placebo (n=192). In total, 125 (66.1%) mitiperstat-treated versus 125 (65.1%) placebo-treated participants experienced COPDCompEx events over 24 weeks. There was no improvement in time to first COPDCompEx event (hazard ratio [HR] 1.07 [90% confidence interval (CI) 0.87, 1.32]; p=0.599) or time to first moderate-to-severe COPD exacerbation (HR 1.23 [90% CI 0.88, 1.73]) with mitiperstat versus placebo. Improvements in post-BD FEV1, respiratory symptoms or disease impact were not seen with mitiperstat. A similar proportion of participants in both groups reported adverse events; seven mitiperstat-treated participants and two placebo-treated participants had pneumonia during the study. CONCLUSION: These results indicate that the risks outweigh the benefits of mitiperstat as a treatment for COPD.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Saralaya D, Mustapa MN, Ferreira J, et al. A phase 2a, double-blind, randomised, placebo-controlled trial of the myeloperoxidase inhibitor, mitiperstat, in participants with chronic obstructive pulmonary disease. Eur Respir J. 2026. PMID: 42562590. doi:10.1183/13993003.02567-2025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。